Bayer Partners with Vanderbilt Medical Center in Five-Year Drug Discovery Collaboration for Cardiovascular and Kidney Diseases
Key Insights
Bayer and Vanderbilt University Medical Center announced a strategic five-year collaboration agreement to advance innovative therapies from target identification through Investigational New Drug application.
The partnership will initially focus on cardiovascular and kidney diseases (search), two therapeutic areas with significant unmet medical need, while spanning across all indications currently pursued by Bayer.
The collaboration will leverage VUMC's comprehensive datasets, including the BioVU collection of DNA and plasma, to enable data-driven insights and accelerate drug discovery and development.
Bayer and Vanderbilt University Medical Center (VUMC) have entered a strategic five-year collaboration agreement to advance innovative therapies from target identification through Investigational New Drug (IND) application. The partnership spans across all indications currently pursued by Bayer, with an initial focus on cardiovascular and kidney diseases (search), two therapeutic areas with significant unmet medical need.
Leveraging Data Resources for Drug Discovery
The collaboration will harness VUMC's resource platform, including its comprehensive datasets hosted in Vanderbilt's BioVU collection of DNA and plasma, to enable data-driven insights and accelerate discovery and development. The partnership combines Bayer's expertise in drug discovery and translational sciences with VUMC's deep preclinical and clinical knowledge.
"This collaboration exemplifies our shared vision to harness cutting-edge science and real-world data to bring innovative treatments to patients faster," said Juergen Eckhardt, M.D., Head of Business Development and Licensing at Bayer Pharmaceuticals. "Collaborating with VUMC underscores our commitment to advancing precision medicine and fostering partnerships that integrate world-class research capabilities with industry-leading development expertise."
Academic Medical Center Capabilities
VUMC brings substantial research infrastructure to the partnership. The academic health system, headquartered in Nashville, Tennessee, is one of the largest and most prominent academic systems in the Southeast U.S. With 43,000 employees, including 4,930 clinicians, VUMC accommodated more than 3.5 million patient visits last year at its seven hospitals and 180+ clinic locations.
Vanderbilt University School of Medicine ranks among the U.S. top 10 in receipt of federal research funding from the National Institutes of Health. In 2025, VUMC contributed $22.13 billion to the regional economy while providing more than $1 billion in total community benefit and investment.
"VUMC has many internationally recognized research faculty along with deep and unique data resources that enable pharmaceutical discovery and development," said Ken Holroyd, M.D., holder of the Brock Family Directorship for Applied Innovation and Vice President for Tech Transfer at VUMC. "We are delighted to enter this new and important collaboration with Bayer. We will complement Bayer's expertise to fulfill our mission to convert research into impactful new treatments for patients."
Strategic Focus on Cardiovascular and Kidney Diseases
Bayer positions itself as a leader in cardiology and is advancing a portfolio of innovative treatments. The company recognizes that the heart and kidneys are closely linked in health and disease, driving its work on new treatment approaches for cardiovascular and kidney diseases (search) with high unmet medical needs.
The company's strategy aims to unlock the strong potential of the future cardiovascular market by transforming Bayer's portfolio into precision cardiology, addressing the high disease burden, and driving long-term growth. Bayer's portfolio already includes several innovative products and compounds in various stages of preclinical and clinical development, reflecting the company's research approach that prioritizes targets and pathways with the potential to impact cardiovascular disease treatment.
Company Background
Bayer operates as a global enterprise with core competencies in the life science fields of health care and nutrition. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros, with R&D expenses amounting to 6.2 billion euros. The company's mission centers on "Health for all, Hunger for none," designing products and services to help people and the planet thrive by addressing challenges presented by a growing and aging global population.